NASDAQ · Biotechnology · USD
Virax Biolabs Group Limited (VRAX) Stock Analysis
Virax Biolabs Group Limited (VRAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
VRAX Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.38
- Previous Close
- $1.37
- Day's Range
- 1.32–1.49
- 52-Week Range
- 1.32–21.75
- Volume
- 14.71K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.39
Valuation
- Market Cap
- $1.80M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 145.08
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −12.64
Financials (FY)
- Revenue (FY)
- $12.42K+96.22%
- Net Income (FY)
- −$5.02M
- Shares Outstanding
- 1.34M
- 1-Year Return
- −91.63%
Dividend and dates
- Avg Volume
- 397.95K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, VRAX closed at $1.34, −91.63% over 1 year.
Virax Biolabs Group Limited (VRAX) has a market capitalization of $1.80M.
In fiscal 2025, VRAX reported revenue of $12.42K.
VRAX Stock Return by Calendar Year
Virax Biolabs Group Limited (VRAX) return since Jul 2022: what $10,000 became
- 1 year
- $10,000 $837
- −91.63%
- 3 years
- $10,000 $195
- −98.05%
- Since Jul 2022
- $10,000 $3
- −99.97%
If you had invested $10,000 in Virax Biolabs Group Limited (VRAX) at the close on July 21, 2022, the earliest close on record here, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −85.22% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −84.51% |
| 2025 | −84.62% |
| 2024 | +54.11% |
| 2023 | −80.00% |
| 2022 (partial year) | −95.99% |
As of October 21, 2026.
VRAX Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $12.42K | −$5.02M | −40,439.1% |
| 2024 | $6.33K | −$6.06M | −95,739.2% |
| 2023 | $156.42K | −$6.73M | −4,304.8% |
| 2022 | $8.56K | −$5.46M | −63,748.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $12.42K | $7.69K | −$6.40M | −$5.02M | −40,439.1% |
| 2024 | $6.33K | −$53.07K | −$6.08M | −$6.06M | −95,739.2% |
| 2023 | $156.42K | $50.59K | −$6.14M | −$6.73M | −4,304.8% |
| 2022 | $8.56K | −$1.37K | −$5.73M | −$5.46M | −63,748.3% |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
VRAX Valuation vs Biotechnology Median
Median of 608 stocks| Metric | VRAX | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 145.08 | 13.30 | 10.9x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B